Drug utilisation study of anti-hypertensive drugs in a tertiary care hospital

Mubeen Musarrath; Jamali Gohar; Fatima Bushra; Bindu Bhashini M; Begum Samreen; Namreen Azra; Naaz Saniya; Fathima Kaneez

doi:10.70604/ijzels.v2i3.84

Authors

Musarrath Mubeen Assistant Professor, Department of Pharmacology, Smt. Sarojini Ramulamma College of Pharmacy, (Palamuru University), Seshadri Nagar, Mahabubnagar District, Telangana State, India.
Gohar Jamali Pharm D, Department of Pharmacy Practice, Smt. Sarojini Ramulamma College of Pharmacy, (Palamuru University), Seshadri Nagar, Mahabubnagar District, Telangana State, India.
Bushra Fatima Pharm D, Department of Pharmacy Practice, Smt. Sarojini Ramulamma College of Pharmacy, (Palamuru University), Seshadri Nagar, Mahabubnagar District, Telangana State, India.
M Bindu Bhashini Pharm D, Department of Pharmacy Practice, Smt. Sarojini Ramulamma College of Pharmacy, (Palamuru University), Seshadri Nagar, Mahabubnagar District, Telangana State, India.
Samreen Begum Pharm D, Department of Pharmacy Practice, Smt. Sarojini Ramulamma College of Pharmacy, (Palamuru University), Seshadri Nagar, Mahabubnagar District, Telangana State, India.
Azra Namreen Pharm D, Department of Pharmacy Practice, Smt. Sarojini Ramulamma College of Pharmacy, (Palamuru University), Seshadri Nagar, Mahabubnagar District, Telangana State, India.
Saniya Naaz Pharm D, Department of Pharmacy Practice, Smt. Sarojini Ramulamma College of Pharmacy, (Palamuru University), Seshadri Nagar, Mahabubnagar District, Telangana State, India.
Kaneez Fathima Pharm D, Department of Pharmacy Practice, Smt. Sarojini Ramulamma College of Pharmacy, (Palamuru University), Seshadri Nagar, Mahabubnagar District, Telangana State, India.

Abstract

Hypertension is a major public health problem, and rational prescribing of antihypertensive drugs is critical for optimizing patient outcomes. The present prospective observational study was conducted over six months in the Department of General Medicine, SVS Medical College and Hospital, Mahbubnagar, to evaluate drug utilization patterns of antihypertensive medications. A total of 150 hypertensive patients were enrolled after applying inclusion criteria, and prescriptions were analyzed for demographic distribution, comorbidities, and prescribing trends. The majority of patients were aged 51–60 years (34.0%), with males being more commonly affected (60%). Diabetes mellitus was the most frequent comorbidity (40%), followed by hypertension alone (37.3%), cerebrovascular accident (8.7%), thyroid disorders (6.7%), hypertensive urgency (3.3%), bronchiolitis (2.7%), and heart failure (1.3%). Monotherapy was predominant, with ACE inhibitors (26.7%) being the most prescribed class, followed by angiotensin receptor blockers (ARBs, 23.3%), calcium channel blockers (20.0%), thiazide diuretics (13.3%), β-blockers (10.0%), and loop diuretics or other agents (3.3%), while fixed-dose combinations were used sparingly (3.3%). Comorbidity profiles largely guided prescribing: ACEI/ARBs were preferred in diabetes, CVA, and heart failure; β-blockers were selectively used in thyroid disorders and heart failure; and non-selective β-blockers were avoided in bronchiolitis. The findings highlight that comorbidity-based prescribing patterns largely aligned with evidence-based recommendations. Early detection, rational drug selection, and reinforcement of lifestyle modifications remain essential to preventing complications and improving long-term management of hypertension.

Keywords:

Hypertension, Drug utilisation study, Antihypertensive drugs, Telmisartan, Amlodipine, ARBs, Calcium channel blockers, Comorbidities

DOI

https://doi.org/10.70604/ijzels.v2i3.84

References

1. Go AS. Heart disease and stroke statistics—2013 update: a report from the American Heart Association. Circulation. 2013;127:E841.

2. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, et al. Heart disease and stroke statistics—2013 update: a report from the American Heart Association. Circulation. 2013;127:E6–245.

3. World Heart Foundation. Hypertension. 2014.

4. Weber MA, Schiffrin EL, White WB, Mann S, Lindholm LH, et al. Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. J Clin Hypertens (Greenwich). 2014;16:14–26.

5. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension. Blood Press. 2013;22:193–278.

6. World Health Organization. Raised blood pressure: situation and trends. 2014.

7. Heidenreich PA, Trogdon JG, Khavjou OA, Butler J, Dracup K, et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation. 2011;123:933–44.

8. Law MR, Morris JK, Wald NJ. Use of blood pressure–lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:b1665.

9. Hales S. Statistical essays, containing haemastaticks. London: W Innys, R Manby, and T. Woodward; 1733.

10. Booth J. A short history of blood pressure measurement. Proc R Soc Med. 1977;70:793–9.

11. Smirk FH. Casual and basal blood pressures IV: their relationship to the supplemental pressure with a note on statistical implications. Br Heart J. 1944;6:176–82.

12. Fisher JW. The diagnostic value of the sphygmomanometer in examinations for life insurance. JAMA. 1914;63:1752–4.

13. Kylin E. Studien: hypertoniehyperglykamiehyperurikamie syndrome. Zentralbl Inn Med. 1923;44.

14. Vague J. [Not available]. Presse Med. 1947;55:339.

15. Frost CD, Law MR, Wald NJ. By how much does dietary salt reduction lower blood pressure? II: analysis of observational data within populations. BMJ. 1991;302(6780):815–8.

16. Guyton AC, Coleman TG, Cowley AV, Scheel KW, Manning RD, Norman RA. Arterial pressure regulation: overriding dominance of the kidneys in long-term regulation and in hypertension. Am J Med. 1972;52:584–94.

17. Fagard R, Brguljan J, Staessen J, Thijs L, Derom C, et al. Heritability of conventional and ambulatory blood pressures: a study in twins. Hypertension. 1995;26:919–24.

18. Warren HR, Evangelou E, Cabrera CP, Gao H, Ren M, et al. Genome-wide association analysis identifies novel blood pressure loci and offers biological insights into cardiovascular risk. Nat Genet. 2017;49:403–15.

19. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19.1 million participants. Lancet. 2017;389:37–55.

20. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19.1 million participants. Lancet. 2017;389:37–55.

21. Danaei G, Ding EL, Mozaffarian D, Taylor B, Rehm J, et al. The preventable causes of death in the United States: comparative risk assessment of dietary, lifestyle, and metabolic risk factors. PLoS Med. 2009;6(4):e1000058.

22. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365:217–23.

23. Keaton JM, Kamali Z, Xie T, Vaez A, Williams A, et al. Genome-wide analysis in over 1 million individuals of European ancestry yields improved polygenic risk scores for blood pressure traits. Nat Genet. 2024;56:778–91.

24. Lifton RP, Gharavi AG, Geller DS. Molecular mechanisms of human hypertension. Cell. 2001;104:545–56.

25. O’Brien E, Beevers DG, Lip GY. ABC of hypertension. London: BMJ Books; 2007.

26. The Pharmaceutical Journal. Hypertension: pathophysiology and diagnosis. Available from: https://pharmaceutical-journal.com/article/ld/hypertension-pathophysiology-and-diagnosis#fn_link_7

27. Weber MA, Schiffrin EL, White WB, Mann S, Lindholm LH, et al. Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. J Clin Hypertens. 2014;16:14–26.

28. Carretero OA, Oparil S. Essential hypertension: part II: treatment. Circulation. 2000;101:446–53.

29. Beevers G, Lip GY, O’Brien E. ABC of hypertension: the pathophysiology of hypertension. BMJ. 2001;322:912–6.

30. Mayet J, Hughes A. Cardiac and vascular pathophysiology in hypertension. Heart. 2003;89:1104–9.

31. Mark AL. The sympathetic nervous system in hypertension: a potential long-term regulator of arterial pressure. J Hypertens Suppl. 1996;14:S159–65.

32. Kim JR, Kiefe CI, Liu K, Williams OD, Jacobs DR Jr, et al. Heart rate and subsequent blood pressure in young adults: the CARDIA study. Hypertension. 1999;33:640–6.

33. Cain AE, Khalil RA. Pathophysiology of essential hypertension: role of the pump, the vessel, and the kidney. Semin Nephrol. 2002;22:3–16.

34. Cody RJ. The sympathetic nervous system and the renin–angiotensin–aldosterone system in cardiovascular disease. Am J Cardiol. 1997;80:9J–14J.

35. Sarzani R, Salvi F, Dessì-Fulgheri P, Rappelli A. Renin–angiotensin system, natriuretic peptides, obesity, metabolic syndrome, and hypertension: an integrated view in humans. J Hypertens. 2008;26:831–43.

36. Ferrario CM. Role of angiotensin II in cardiovascular disease: therapeutic implications of more than a century of research. J Renin Angiotensin Aldosterone Syst. 2006;7:3–14.

37. Piepho RW, Beal J. An overview of antihypertensive therapy in the 20th century. J Clin Pharmacol. 2000;40:967–77.

38. Simões E Silva AC, Flynn JT. The renin–angiotensin–aldosterone system in 2011: role in hypertension and chronic kidney disease. Pediatr Nephrol. 2012;27:1835–45.

Drug utilisation study of anti-hypertensive drugs in a tertiary care hospital

Authors

Abstract

Keywords:

DOI

References

Published

How to Cite

Issue

Section

How to Cite